The incorporation of immunotherapy into the armamentarium of cancer treatments has resulted in significant improvements in outcomes for many patients with advanced cancers. Dr. Robert Chin and Dr. Deborah Wong discuss the benefits of integrating immunotherapy into radiotherapy regimens.
Are we at the beginning of an era in which most cancers may be controlled or even cured with immunotherapy; or are we simply at the end of the beginning of this new field of contemporary immunotherapy?
Pseudoprogression may be associated with mixed responses, which include shrinkage concomitant with increased tumor size or even new lesions appearing elsewhere. Clinicians may struggle with whether to discontinue potentially effective therapy based on a misinterpretation of scan results.
There is a drive to identify potential responders PD-1/PD-L1 through standardized PD-L1 staining techniques, which has led to debates about diagnostic techniques and what should be considered the threshold for a “positive” finding.